Hosted on MSN1mon
Scientists discover a rare missense variant in STAT6 that protects against asthma
Downregulating STAT6 in a clinical setting may, therefore, combine the effects of many of these drugs, making it an attractive target for drug development to treat severe, uncontrolled T2 high asthma.
Hosted on MSN3mon
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
STAT6 is a historically undrugged essential transcription factor in the IL-4/IL-13 signaling pathways and the central driver of T helper type 2 (TH2) inflammation in allergic diseases. Sanofi SNY ...
Business Wire1mon
DeepCure Unveils STAT6 Inhibitor Program with Novel Oral Small Molecules Targeting Type 2 Inflammation
These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a ...
Nasdaq24d
Gilead, LEO Pharma Enter Strategic Partnership To Accelerate Development Of Oral STAT6 Program
(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...
MedCity News24d
Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target
Gilead Sciences’ inflammation drug prospects have come via deals, and the latest one brings drug candidates for an elusive target that’s in pursuit by a growing number of companies. The ...
BioWorld23d
Gilead and Leo Pharma partner on oral STAT6 program
Gilead Sciences Inc. and Leo Pharma A/S have established a strategic partnership to accelerate the development and commercialization of Leo’s small-molecule oral STAT6 programs for the treatment of ...
The EMBO Journal1d
Type-2 innate signals are dispensable for skeletal muscle regeneration and pathology linked to Duchenne muscular dystrophy
Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...
FierceBiotech24d
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
The development and commercialization deal zeros in on Leo’s preclinical STAT6 research programs, according to the Jan. 11 release. The transcription factor is used for IL-4 and IL-13 cytokine ...
Yahoo Finance22d
Gilead, LEO Pharma Partner in $1.7 Billion Deal for Inflammatory Disease Therapies
Driven inflammatory disorders like asthma, chronic obstructive pulmonary disease, and atopic dermatitis, the cooperation centers on STAT6, a transcription factor associated with IL-4 and IL-13 ...
Nature8mon
NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway
We found that interleukin 4 receptor (IL-4R) knockout and downstream signal transducer and activator of transcription 6 (STAT6) knockout, but not IL-4 knockout, mice resisted tumor recurrence ...
PharmaTimes23d
Gilead and LEO Pharma partner to develop oral STAT6 program
Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory ...